Effect of the Olive Leaf Tea Ingestion in Post-prandial Glycemic Response (OLIFTEA) (OLIFTEA)

May 25, 2022 updated by: Manuela Meireles, Instituto Politécnico de Bragança
This study tests the effect of Olive Tea Ingestion in ameliorating glycemic response after a high-glycemic meal

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This study is a double-blinded, randomized, placebo-controlled clinical trial with cross-over design.

Study Type

Interventional

Enrollment (Anticipated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Portugal
      • Bragança, Portugal, 5300-253
        • Recruiting
        • Escola Superior de Saúde
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

-

Exclusion Criteria:

  • currently taking drugs interfering with glucose regulation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Olive Leaf Tea
Other: Olive leaf tea
250 mL of Olive leaf tea and a high-glycemic breakfast
Placebo Comparator: Placebo tea
Other: Placebo tea
250 mL of placebo tea and a high-glycemic breakfast

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood glucose
Time Frame: 120 minutes
Area under the curve
120 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Instituto Politécnico de Bragança

Investigators

  • Principal Investigator: Manuela Meireles, PhD, Instituto Politécnico de Bragança

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 29, 2022

Primary Completion (Anticipated)

June 30, 2022

Study Completion (Anticipated)

June 30, 2022

Study Registration Dates

First Submitted

May 25, 2022

First Submitted That Met QC Criteria

May 25, 2022

First Posted (Actual)

May 31, 2022

Study Record Updates

Last Update Posted (Actual)

May 31, 2022

Last Update Submitted That Met QC Criteria

May 25, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 361221

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Blood Glucose

Clinical Trials on Olive leaf tea

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe